12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vantictumab: Phase Ib started

OncoMed began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate IV vantictumab in combination with Abraxane nab-paclitaxel and gemcitabine in up to about 34 patients. Vantictumab is also in Phase Ib trials in patients...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >